CD40L Inhibitor Frexalimab to be Tested in Phase 3 Trials of Relapsing MS and Non-Relapsing Secondary Progressive MS
Frexalimab, an investigational CDL40 inhibitor, will be assessed in 2 phase 3 trials, dubbed FREXALT (NCT06141473) and FREVIVA (NCT06141486), that will assess the efficacy and safety of the agent in patients with relapsing multiple sclerosis (MS) and non- …